Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 2, 2008, Pages 272-280

  Liu, Guozheng ^a   Dou, Shuping ^a   Pretorius, P Hendrik ^a   Liu, Xinrong ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

99mTc; Biodistribution; Drug delivery; Molecular imaging; Monoclonal antibody

Indexed keywords

ANTIBODY; INDIUM 111; MORF B72.3 ANTIBODY; TAG 72 ANTIBODY; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE MODEL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE TUMOR; RADIOACTIVITY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; MALE; MICE; MICE, INBRED BALB C; MORPHOLINES; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TECHNETIUM; TREATMENT OUTCOME;

EID: 38349159550     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0606-z     Document Type: Article

References (36)

1. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005;11:7879-85.
2. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5.
3. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340-8.
4. Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003;44:437-45.
5. Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996;37:967-71.
6. Sung C, van Osdol WW. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 1995;36:867-76.
7. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, et al. Antibodies against metal chelates. Nature 1985;316 6025:265-8.
8. Goodwin DA, Meares CF, MnTigue M, et al. Rapid localization of haptens in sites containing previously administrated antibody for immunoscintigraphy with short half-life tracers [abstract]. J Nucl Med 1986;27:959 (suppl).
9. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-302.
10. 99mTc-labeled morpholino, a DNA analog. J Nucl Med 2002;43:384-91.
11. Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004;31:417-24.
12. Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice-establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging 2005;32:1115-23.
13. Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 2007;34:237-46
14. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-76.
15. Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
16. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
17. Mazur MT, Shultz JJ. Prostatic adenocarcinoma. Evaluation of immunoreactivity to monoclonal antibody B72.3. Am J Clin Pathol 1990;93:466-70.
18. Badalament RA, Burgers JK, Petty LR, Mojzisik CM, Berens A, Marsh W, et al. Radioimmunoguided radical prostatectomy and lymphadenectomy. Cancer 1993;71:2268-75.
19. Myers RB, Meredith RF, Schlom J, LoBuglio AF, Bueschen AJ, Wheeler RH, et al. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol 1994;152:243-6.
20. Myers RB, Schlom J, Srivastava S, Grizzle WE. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Mod Pathol 1995;8:260-5.
21. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-22.
22. Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, et al. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol 1995;153:1575-9.
23. Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986;76:995-1006.
24. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-24.
25. Loy TS, Nashelsky MB. Reactivity of B72.3 with adenocarcinomas. An immunohistochemical study of 476 cases. Cancer 1993;72:2495-8.
26. Starling JJ, Maciak RS, Law KL, Hinson NA, Briggs SL, Laguzza BC, et al. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Cancer Res 1991;51:2965-72.
27. 3 for technetium-99m labeling of DNA. Nucl Med Biol 1997;24:425-32.
28. 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot 2006;64:971-8.
29. He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem 2007;18:983-8.
30. Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, et al. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate 2006;66:1474-86.
31. van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, et al. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA (In) antibody in 3 RCC models. J Nucl Med 2005;46:495-501.
32. van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride BJ, Goldenberg DM, et al. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med 2005;46:1016-22.
33. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 1998;58:3009-14.
34. Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol 2002;29:783-90.
35. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45:519-25.
36. 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004;45:1390-7.